Federal contractor · MOUNTAIN VIEW, CA

NEUCYTE INC

No contract obligations recorded for NEUCYTE INC in FY2026. Since FY2021: $601.5K.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
X263NRWQNLL6
Small businessMinority-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 64.5KFY2021
  2. 537KFY2024

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for NEUCYTE INC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

NEUCYTE INC received $0 in federal assistance in FY2026, on 1 actions (0 new awards).

Assistance · FY2026
$0
New awards
0
Actions
1
Since FY2023
$1M

Assistance by fiscal year

  1. 500KFY2023
  2. 500KFY2024
  3. 0FY2025
  4. 0FY2026

Largest awards

  1. NANOLUCIFERASE-BASED AD/ADRD MICROPHYSIOLOGICAL SYSTEMS PLATFORM FOR HIGH-THROUGHPUT SCREENING - ABSTRACT ALZHEIMER DISEASE (AD) IS…$500K
    93.866 · Aging Research· National Institutes of Health· Project grant· Sep 12, 2024 – Mar 30, 2026· R41AG085831

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2023–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 2 markets (agency × industry), FY2024–FY2026.

  1. GENCYTE THERAPEUTICS INC$500K−100% in FY2026
    SAN CARLOS, CA · 93% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. EYDIS BIO, INC.$499.8K−100% in FY2026
    DURHAM, NC · 93% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. NOMOCAN PHARMACEUTICALS LLC$499.2K−100% in FY2026
    NEW YORK, NY · 93% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026.